Merck Didn't Spin Off Organon to Set It Free. It Spun Off Organon to Get Paid.

On June 2, 2021, every Merck shareholder woke up owning a new company.⁴ For every ten Merck shares, they received one share of Organon & Co. — a freshly listed business holding the women's health drugs, the biosimilars, and the established brands Merck had decided it no longer wanted to carry.² The press release language was the language of liberation: a focused Merck, an independent Organon, both free to chase their own destinies. What that language quietly skipped over is the part that actually moved money. On its way out the door, Organon had borrowed about $9.5 billion — and handed roughly $9.0 billion of it straight back to the parent.³

The official story is that Merck spun off Organon to focus on cancer. The truer story is that Merck spun off Organon to get paid for the businesses it was leaving behind — and to leave the bill with the company it was leaving.

The cash didn't come from Merck. It came out of Organon.

Here is the mechanism, and it is easy to miss because it runs in the opposite direction from how a spinoff is supposed to feel. A normal divestiture sells an asset and the buyer's cash flows in. A leveraged spinoff does something cleverer: the asset borrows the money itself, then pays that money to the parent before it leaves. Organon expected about $9.5 billion of total debt at separation; approximately $9.0 billion of it was distributed directly back to Merck as a cash payment tied to the split.³ So the slow-growth legacy portfolio that Merck no longer wanted was not merely set free — it was first mortgaged, and the proceeds of the mortgage stayed with Merck. The new company stepped into the public markets already nine-and-a-half billion dollars in the hole, on day one, before it sold a single pill.

Merck dressed this in the standard strategic vocabulary, and the vocabulary was real enough. It wanted to concentrate on its growth pillars — oncology, vaccines, hospital and specialty, animal health — which it expected to drive roughly 90% of its revenue growth after the split.⁵ It wanted a leaner footprint, cutting its human-health manufacturing footprint by about a quarter and its product count by about half.⁵ It targeted over $1.5 billion in operating efficiencies by 2024 and a non-GAAP operating margin above 40%.⁶ All true. But notice what each of those goals quietly assumes: that the most valuable thing about the legacy business was getting it off the books. The cash distribution wasn't a side effect of the focus. It was the focus, denominated in dollars.

What Merck did with the money — and why it cut against the story

If the spinoff were really about reducing risk, the freed cash would have gone toward diversification. It went the other way. The roughly $9 billion infusion was earmarked for M&A by Merck's incoming chief executive⁸, deepening rather than diluting the company's central bet. And that bet had a name: Keytruda. By stripping out a diversified base of older, steadier products, Merck made itself more dependent on its blockbuster cancer immunotherapy, not less. By 2025 Keytruda was generating over $30 billion — nearly half of all of Merck's revenue.⁸ The 'focus' the spinoff delivered was also a concentration, and concentration is the polite word for risk.

The proof that this concentration was a problem is that Merck is still trying to solve it. In February 2026, the company announced it would carve out a separate cancer division, partly to manage the very Keytruda exposure the Organon split had sharpened — with the drug's patent cliff now in view.⁸ A company that had genuinely de-risked in 2021 would not be performing structural surgery on the same risk five years later. The Organon spinoff didn't fix the concentration. It funded it.

Even the name tells on the strategy. Organon wasn't a clean-slate brand invented to inspire a new company; it was an old Dutch name Merck had owned since the 2009 Schering-Plough acquisition and chose to revive for its women's-health equity.⁷ The 'women's health champion' framing was the marketing story for the asset being sold — a way to make a portfolio of mature products sound like a mission. It was never the reason Merck did the deal.

Isn't this just a normal, well-run spinoff?

The fair objection is that none of this is sinister — leveraged spinoffs are a standard, value-creating tool, and Merck's stated logic holds up. A focused company really can outperform a sprawling one; a slow-growth portfolio really can thrive better outside the shadow of a blockbuster. The timeline was orderly, too: Merck announced the move in February 2020 and completed it in June 2021, squarely within the first-half-of-2021 window it had promised from the start.¹⁴ This was a planned, disclosed, sixteen-month operation, not a panic. All true — and it sharpens rather than softens the point. The mechanics were clean precisely because the goal was clean: extract maximum cash from a business on the way out while handing it the debt that made the cash possible. The honest read isn't that Merck did something underhanded. It's that the 'strategic focus' narrative obscures a financing decision that was the actual event. Merck didn't lose Organon. It liquefied it.

Merck spent sixteen months and a great deal of investor-relations craft framing the Organon split as a story about what it wanted to become. The more durable truth is a story about what it wanted to extract. It took roughly nine billion dollars out of a business it was discarding, left the borrowing behind, and poured the proceeds back into the one drug it could least afford to be wrong about. The spinoff worked exactly as designed — which is why, five years on, Merck is back at the operating table, cutting at the same concentration the first cut helped create. The deal was never a choice to give something up. It was a choice about who would hold the debt while Merck doubled down.